William Oh/Linkedin
Oct 3, 2023, 17:22
William Oh: For men with aggressive prostate cancer, genetic testing can inform treatment decisions.
Quoting William Oh, Chief Medical Officer of Prostate Cancer Foundation, on LinkedIn:
”Germline exome sequencing of over 17k men of European ancestry with aggressive and non-aggressive prostate cancer showed an association between the known genes BRCA2, ATM, and NBN with aggressive prostate cancer, in addition to evidence of a link to rare variants in MSH2, XRCC2, and MRE11A. For men with aggressive prostate cancer, genetic testing can inform treatment decisions. We need similar datasets in non-European populations.”
For the article click here.
Source: William Oh/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19